Therapy News and Research

RSS

Akonni to develop closed amplicon RT-PCR microarray for virus detection in CSF

Akonni Biosystems, a molecular diagnostics company that develops novel nucleic acid extraction and microarray-based testing systems designed to rapidly and economically analyze biological samples, today announced receipt of a $300K grant from the National Institutes of Health.

5 Aug 2011

News media registration now open for ASM annual infectious diseases meeting

News media registration for the annual infectious diseases meeting of the American Society for Microbiology (ASM) is now open.

5 Aug 2011

Scientists convert human skin cells into forebrain neurons

Columbia University Medical Center researchers have for the first time directly converted human skin cells into functional forebrain neurons, without the need for stem cells of any kind.

5 Aug 2011

PCF funds 10 new Challenge Awards for prostate cancer research

The Prostate Cancer Foundation today announced that it has funded 10 new Challenge Awards for accelerating scientific discovery and new treatments for prostate cancer patients.

5 Aug 2011

Roadmap to overcome obstacles for using induced pluripotent stem cells

The possibility of developing stem cells from a patient's own skin and using them to treat conditions as diverse as Parkinson's disease, Alzheimer's disease and cancer has generated tremendous excitement in the stem cell research community in recent years. Such therapies would avoid the controversial need for using stem cells derived from human embryos, and in theory, also bypass immunological problems inherent in using cells from one person to treat another.

5 Aug 2011

Shear stress-based method can identify vulnerable plaque in coronary arteries

Researchers at Emory and Georgia Tech have developed a method for predicting which areas of the coronary arteries will develop more atherosclerotic plaque over time, based on intracoronary ultrasound and blood flow measurements.

5 Aug 2011

Dyax initiates ecallantide Phase 2 trial for ACE inhibitor-induced angioedema

Dyax Corp. announced today treatment of the first patient in a Phase 2 trial evaluating the efficacy and safety of ecallantide, a potent, selective, reversible inhibitor of plasma kallikrein, for acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema.

4 Aug 2011

Palatin confirms initiation of AZD2820 Phase 1 trial in obesity

Palatin Technologies, Inc. confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity.

4 Aug 2011

RNAi screen identifies Brd4 as a therapeutic target for acute myeloid leukemia

Scientists at Cold Spring Harbor Laboratory (CSHL) and five other institutions have used an unconventional approach to cancer drug discovery to identify a new potential treatment for acute myeloid leukemia.

4 Aug 2011

Micromet second quarter total revenues increase to $7.1 million

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the second quarter and six months ended June 30, 2011.

4 Aug 2011

NanoString to begin clinical development program for Breast Cancer Intrinsic Subtyping Assay

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced that it is initiating the first in a series of studies to evaluate the clinical utility of the NanoString Breast Cancer Intrinsic Subtyping Assay.

From NanoString Technologies 4 Aug 2011

Positive results from hGH-CTP Phase II trial in growth hormone deficient adults

PROLOR Biotech, Inc. today reported positive results from a Phase II clinical trial of its long-acting CTP-modified version of human growth hormone (hGH-CTP) in growth hormone deficient adults.

4 Aug 2011

BioCryst second quarter total revenues decrease to $3.7 million

BioCryst Pharmaceuticals, Inc. announced financial results for the second quarter and six months ended June 30, 2011.

4 Aug 2011

NIA, ACRO collaborate to create disease site-specific radiation oncology practice guidelines

National Imaging Associates (NIA), a subsidiary of Magellan Health Services, and the American College of Radiation Oncology (ACRO), the professional medical society established for educational and scientific purposes to advance the science and practice of radiation oncology, today announced the signing of a collaborative agreement.

4 Aug 2011

Metallofullerene-based nanoplatform shows promise against glioblastomas

Researchers from two universities have developed and tested a molecular platform that offers hope for treatment of aggressive brain tumors.

4 Aug 2011

Technology-enabled pharmacists to make house calls

The University of Rhode Island's College of Pharmacy is pairing home visits from pharmacists with the latest technology, providing instant access to a patient's medical history and medications, all in an effort to reduce hospital readmissions.

4 Aug 2011

New research highlights urgent need to develop specific guidelines for HIV-infected children

Children with HIV have persistently high levels of cholesterol and other lipids during treatment with antiretroviral medications, according to a pair of studies in JAIDS: Journal of Acquired Immune Deficiency Syndromes.

4 Aug 2011

Positive activity interventions effective in treatment of depressive disorders

Positive activity interventions (PAIs) offer a safe, low-cost, and self-administered approach to managing depression and may offer hope to individuals with depressive disorders who do not respond or have access to adequate medical therapy, according to a comprehensive review article in The Journal of Alternative and Complementary Medicine, a peer-reviewed journal published by Mary Ann Liebert, Inc.

4 Aug 2011

Innovative delivery systems and methods to treat breast cancer

In their lifetime, women have more than a 12 percent risk of being diagnosed with breast cancer. 1 This week, research on novel approaches to breast cancer treatment is being presented at the Era of Hope (EOH) conference, a scientific meeting hosted by the Department of Defense Breast Cancer Research Program (BCRP).

4 Aug 2011

Avaxia receives BARDA contract to develop new radiation mitigation drug

Avaxia Biologics, Inc., a privately-held biotech company developing oral antibody drugs that act locally within the gastrointestinal tract, announced today it was awarded a contract with the Biomedical Advanced Research and Development Authority (BARDA), for the research and development of an oral antibody therapy to mitigate the gastrointestinal damage that follows radiation exposure that might occur after a nuclear incident.

4 Aug 2011